Literature DB >> 11895474

Phosphorylation and reorganization of vimentin by p21-activated kinase (PAK).

Hidemasa Goto1, Kazushi Tanabe, Edward Manser, Louis Lim, Yoshihiro Yasui, Masaki Inagaki.   

Abstract

BACKGROUND: Intermediate filament (IF) is one of the three major cytoskeletal filaments. Vimentin is the most widely expressed IF protein component. The Rho family of small GTPases, such as Cdc42, Rac and Rho, are thought to control the organization of actin filaments as well as other cytoskeletal filaments.
RESULTS: We determined if the vimentin filaments can be regulated by p21-activated kinase (PAK), one of targets downstream of Cdc42 or Rac. In vitro analyses revealed that vimentin served as an excellent substrate for PAK. This phosphorylated vimentin lost the potential to form 10 nm filaments. We identified Ser25, Ser38, Ser50, Ser65 and Ser72 in the amino-terminal head domain as the major phosphorylation sites on vimentin for PAK. The ectopic expression of constitutively active PAK in COS-7 cells induced vimentin phosphorylation. Fibre bundles or granulates of vimentin were frequent in these transfected cells. However, the kinase-inactive mutant induced neither vimentin phosphorylation nor filament reorganization.
CONCLUSION: Our observations suggest that PAK may regulate the reorganization of vimentin filaments through direct vimentin phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11895474     DOI: 10.1046/j.1356-9597.2001.00504.x

Source DB:  PubMed          Journal:  Genes Cells        ISSN: 1356-9597            Impact factor:   1.891


  41 in total

Review 1.  Vimentin in cancer and its potential as a molecular target for cancer therapy.

Authors:  Arun Satelli; Shulin Li
Journal:  Cell Mol Life Sci       Date:  2011-06-03       Impact factor: 9.261

Review 2.  PAK1 as a therapeutic target.

Authors:  Julia V Kichina; Anna Goc; Belal Al-Husein; Payaningal R Somanath; Eugene S Kandel
Journal:  Expert Opin Ther Targets       Date:  2010-07       Impact factor: 6.902

3.  Microtubule-dependent transport of vimentin filament precursors is regulated by actin and by the concerted action of Rho- and p21-activated kinases.

Authors:  Amélie Robert; Harald Herrmann; Michael W Davidson; Vladimir I Gelfand
Journal:  FASEB J       Date:  2014-03-20       Impact factor: 5.191

4.  Type I keratin 17 protein is phosphorylated on serine 44 by p90 ribosomal protein S6 kinase 1 (RSK1) in a growth- and stress-dependent fashion.

Authors:  Xiaoou Pan; Lesley A Kane; Jennifer E Van Eyk; Pierre A Coulombe
Journal:  J Biol Chem       Date:  2011-10-17       Impact factor: 5.157

5.  Molecular diversity of rat brain proteins as revealed by proteomic analysis.

Authors:  Jae-Won Yang; Jean-François Juranville; Harald Höger; Michael Fountoulakis; Gert Lubec
Journal:  Mol Divers       Date:  2005       Impact factor: 2.943

Review 6.  Intermediate filaments in smooth muscle.

Authors:  Dale D Tang
Journal:  Am J Physiol Cell Physiol       Date:  2008-02-06       Impact factor: 4.249

7.  Imperfect asymmetry: The mechanism governing asymmetric partitioning of damaged cellular components during mitosis.

Authors:  Sundararaghavan Pattabiraman; Daniel Kaganovich
Journal:  Bioarchitecture       Date:  2015-05-05

Review 8.  Posttranslational modifications of desmin and their implication in biological processes and pathologies.

Authors:  Daniel L Winter; Denise Paulin; Mathias Mericskay; Zhenlin Li
Journal:  Histochem Cell Biol       Date:  2013-10-04       Impact factor: 4.304

9.  Filamin A is required for vimentin-mediated cell adhesion and spreading.

Authors:  Hugh Kim; Fumihiko Nakamura; Wilson Lee; Yulia Shifrin; Pamela Arora; Christopher A McCulloch
Journal:  Am J Physiol Cell Physiol       Date:  2009-09-23       Impact factor: 4.249

10.  Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies.

Authors:  Guy Lahat; Quan-Sheng Zhu; Kai-Lieh Huang; Suizhao Wang; Svetlana Bolshakov; Jeffery Liu; Keila Torres; Robert R Langley; Alexander J Lazar; Mien Chie Hung; Dina Lev
Journal:  PLoS One       Date:  2010-04-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.